Historical Perspective: Models of Parkinson's Disease

被引:216
|
作者
Chia, Shyh Jenn [1 ]
Tan, Eng-King [1 ,2 ,3 ]
Chao, Yin-Xia [1 ,2 ,3 ]
机构
[1] Natl Neurosci Inst, Singapore 308433, Singapore
[2] Singapore Gen Hosp, Dept Neurol, Singapore 169856, Singapore
[3] Duke NUS Med Sch, Singapore 169857, Singapore
基金
英国医学研究理事会;
关键词
Parkinson disease models; neurotoxic models; genetic models; advantages; limitations; ALPHA-SYNUCLEIN; MOUSE MODEL; PRIMATE MODELS; MOTOR DEFICITS; ANIMAL-MODELS; LRRK2; KINASE; MPTP; MUTATIONS; PARAQUAT; ROTENONE;
D O I
10.3390/ijms21072464
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor signs. The current therapeutic regimen for PD is mainly symptomatic as the etio-pathophysiology has not been fully elucidated. A variety of animal models has been generated to study different aspects of the disease for understanding the pathogenesis and therapeutic development. The disease model can be generated through neurotoxin-based or genetic-based approaches in a wide range of animals such as non-human primates (NHP), rodents, zebrafish, Caenorhabditis (C.) elegans, and drosophila. Cellular-based disease model is frequently used because of the ease of manipulation and suitability for large-screen assays. In neurotoxin-induced models, chemicals such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat are used to recapitulate the disease. Genetic manipulation of PD-related genes, such as alpha-Synuclein(SNCA), Leucine-rich repeat kinase 2 (LRRK2), Pten-Induced Kinase 1 (PINK1), Parkin(PRKN), and Protein deglycase (DJ-1) Are used in the transgenic models. An emerging model that combines both genetic- and neurotoxin-based methods has been generated to study the role of the immune system in the pathogenesis of PD. Here, we discuss the advantages and limitations of the different PD models and their utility for different research purposes.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Diagnosing Parkinson's disease: The patient perspective
    Gofton, Teneille E.
    Jog, Mandar
    CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 2008, 35 (04) : 510 - 512
  • [42] Parkinson's disease from the patient perspective
    Mischley, L.
    Canada, G.
    Lau, R.
    MOVEMENT DISORDERS, 2017, 32
  • [43] Living with Parkinson's disease: A Jordanian perspective
    Nazzal, Mohammad S.
    Khalil, Hanan
    SCANDINAVIAN JOURNAL OF OCCUPATIONAL THERAPY, 2017, 24 (01) : 74 - 82
  • [44] The burden of Parkinson's disease: a worldwide perspective
    Rocca, Walter A.
    LANCET NEUROLOGY, 2018, 17 (11): : 928 - 929
  • [45] Caregiving in Parkinson's Disease: An International Perspective
    Book, E.
    Dawson, R.
    Allen, A.
    Kapust, L.
    McKenzie, J.
    Ueda, M.
    Yu, A.
    MOVEMENT DISORDERS, 2021, 36 : S499 - S499
  • [46] Genetics of Parkinson's Disease - A Clinical Perspective
    Cheon, Sang-Myung
    Chan, Lilian
    Chan, Daniel Kam Yin
    Kim, Jae Woo
    JOURNAL OF MOVEMENT DISORDERS, 2012, 5 (02) : 33 - 41
  • [47] Living With Parkinson's Disease: A Jordanian Perspective
    Nazzal, Mohammad
    Khalil, Hanan
    AMERICAN JOURNAL OF OCCUPATIONAL THERAPY, 2017, 71 (04):
  • [48] Neuroimaging in Parkinson's disease: a future perspective
    Brooks, David J.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (02) : 105 - 108
  • [49] Rethinking Parkinson's Disease: A Syndromic Perspective
    Korczyn, Amos D.
    MOVEMENT DISORDERS, 2024, 39 (06) : 1079 - 1080
  • [50] Global Perspective on Telemedicine for Parkinson's Disease
    Shalash, Ali
    Spindler, Meredith
    Cubo, Esther
    JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S11 - S18